Geraldine Harriman
About Geraldine Harriman
Geraldine Harriman is a seasoned professional in drug discovery and development, currently serving as the Co-Founder and Chief Scientific Officer with over 20 years of experience in the field.
Geraldine Harriman: Co-Founder and Chief Scientific Officer
Geraldine Harriman holds the position of Co-Founder and Chief Scientific Officer. With over 20 years of experience in drug discovery and early development, she has made significant contributions in the medical and scientific fields. Geraldine’s passion for innovation, chemistry, and biology motivated her to delve into the intricacies of medicine, aiming to discover new and effective drugs. Her extensive career showcases her dedication and expertise in the industry.
Geraldine Harriman's Educational Background
Geraldine Harriman received her Ph.D. in Chemistry from the University of Rhode Island, strongly grounding her in the sciences. Furthering her expertise, she completed a post-doctoral fellowship at The University of Kansas. These academic achievements laid the foundation for her subsequent pioneering work in drug discovery and development.
Geraldine Harriman's Experience in Drug Discovery
Geraldine Harriman has extensive experience in drug discovery, marked by key roles at various leading companies. She served as Vice President and Head of ACC Program at Nimbus Therapeutics, where she led the initiative to discover a leading drug for NASH. Prior to this, she was Vice President at Galenea and co-led the Inflammation Therapeutic Area at Millennium Pharmaceuticals. Her expertise also includes being a founding member of the scientific team at LeukoSite.
Geraldine Harriman's Work at Nimbus Therapeutics
At Nimbus Therapeutics, Geraldine Harriman served as Vice President and Head of the ACC Program. In this role, she spearheaded efforts to develop a leading drug for NASH (Nonalcoholic Steatohepatitis), showcasing her ability to lead complex drug discovery projects. Her leadership and scientific acumen were critical in advancing Nimbus Therapeutics' goals in the healthcare industry.